Literature DB >> 16543533

Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Y Davidson1, L Gibbons, A Pritchard, J Hardicre, J Wren, J Tian, J Shi, C Stopford, C Julien, J Thompson, A Payton, U Thaker, A J Hayes, T Iwatsubo, S M Pickering-Brown, N Pendleton, M A Horan, A Burns, N Purandare, C L Lendon, D Neary, J S Snowden, D M A Mann.   

Abstract

Genetic variations represent major risk factors for Alzheimer's disease (AD). While familial early onset AD is associated with mutations in the amyloid precursor protein and presenilin genes, only the e4 allele of the apolipoprotein E (APOE) gene has so far been established as a genetic risk factor for late onset familial and sporadic AD. It has been suggested that the C-->T (224Ala-->Val) transition within exon 2 of the cathepsin D gene (CTSD) might represent a risk factor for late onset AD. The objective of this study was to investigate whether possession of the CTSD exon 2 T allele increases the risk of developing AD, and to determine whether this modulates the amyloid pathology of the disease in conjunction with, or independent of, the APOE e4 allele. Blood samples were obtained from 412 patients with possible or probable AD and brain tissues from a further 148 patients with AD confirmed by postmortem examination. CTSD and APOE genotyping were performed by PCR on DNA extracted from blood, or from frontal cortex or cerebellum in the postmortem cases. Pathological measures of amyloid beta protein (Abeta), as plaque Abeta40 and Abeta42(3) load and degree of cerebral amyloid angiopathy were made by image analysis or semiquantitative rating, respectively. CTSD genotype frequencies in AD were not significantly different from those in control subjects, nor did these differ between cases of early or late onset AD or between younger and older controls. There was no gene interaction between the CTSD T and APOE e4 alleles. The amount of plaque Abeta40 was greater in patients carrying the CTSD T allele than in non-carriers, and in patients bearing APOE e4 allele compared with non-carriers. Possession of both these alleles acted synergistically to increase levels of plaque Abeta40, especially in those individuals who were homozygous for the APOE e4 allele. Possession of the CTSD T allele had no effect on plaque Abeta42(3) load or degree of CAA. Possession of the CTSD T allele does not increase the risk of developing AD per se, but has a modulating effect on the pathogenesis of the disorder by increasing, in concert with the APOE e4 allele, the amount of Abeta deposited as senile plaques in the brain in the form of Abeta40.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543533      PMCID: PMC2077521          DOI: 10.1136/jnnp.2005.063917

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  Cathepsin D: screening for new polymorphisms using single-strand conformation polymorphism analysis.

Authors:  Micael Majores; Heike Kolsch; Metin Bagli; Andreas Papassotiropoulos; Petra Louise Lohmann; Sandra Schmitz; Marie Luise Rao; Wolfgang Maier; Reinhard Heun
Journal:  Int J Mol Med       Date:  2002-02       Impact factor: 4.101

2.  A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease.

Authors:  A Papassotiropoulos; M Bagli; A Kurz; J Kornhuber; H Förstl; W Maier; J Pauls; N Lautenschlager; R Heun
Journal:  Ann Neurol       Date:  2000-03       Impact factor: 10.422

3.  Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.

Authors:  Anne M Fagan; Melanie Watson; Maia Parsadanian; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Neurobiol Dis       Date:  2002-04       Impact factor: 5.996

4.  Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease.

Authors:  T J Bhojak; S T DeKosky; M Ganguli; M I Kamboh
Journal:  Neurosci Lett       Date:  2000-07-07       Impact factor: 3.046

5.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

6.  Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer's disease: a HuGE gene-disease association review.

Authors:  Christos Ntais; Anastasia Polycarpou; John P A Ioannidis
Journal:  Am J Epidemiol       Date:  2004-03-15       Impact factor: 4.897

7.  Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer's disease.

Authors:  J Tian; J Shi; K Bailey; D M A Mann
Journal:  Neuropathol Appl Neurobiol       Date:  2004-02       Impact factor: 8.090

8.  Cathepsin D exon 2 polymorphism associated with general intelligence in a healthy older population.

Authors:  A Payton; F Holland; P Diggle; P Rabbitt; M Horan; Y Davidson; L Gibbons; J Worthington; W E R Ollier; N Pendleton
Journal:  Mol Psychiatry       Date:  2003-01       Impact factor: 15.992

9.  Cathepsin D polymorphism in Italian elderly subjects with sporadic late-onset Alzheimer's disease.

Authors:  Tiziana Ingegni; Giuseppe Nocentini; Elena Mariani; Liana Spazzafumo; M Cristina Polidori; Antonio Cherubini; Marco Catani; Donatella Cadini; Umberto Senin; Patrizia Mecocci
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

10.  Association between cathepsin D polymorphism and Alzheimer's disease in a Chinese Han population.

Authors:  Xiao-Qing Li; Deng Chen; Zhen-Xin Zhang; Qiu-Ming Qu; Jun-Wu Zhang
Journal:  Dement Geriatr Cogn Disord       Date:  2004-06-18       Impact factor: 2.959

View more
  11 in total

1.  Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinson's Disease: A Study from Eastern India.

Authors:  Prosenjit Pal; Tamal Sadhukhan; Subhadip Chakraborty; Sriparna Sadhukhan; Arindam Biswas; Shyamal K Das; Kunal Ray; Jharna Ray
Journal:  Neuromolecular Med       Date:  2019-05-28       Impact factor: 3.843

2.  Gene-class analysis of expression patterns induced by psychoactive pharmaceutical exposure in fathead minnow (Pimephales promelas) indicates induction of neuronal systems.

Authors:  Michael A Thomas; Parag P Joshi; Rebecca D Klaper
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2011-06-06       Impact factor: 3.228

3.  Progranulin Stimulates the In Vitro Maturation of Pro-Cathepsin D at Acidic pH.

Authors:  Victoria J Butler; Wilian A Cortopassi; Andrea R Argouarch; Sam L Ivry; Charles S Craik; Matthew P Jacobson; Aimee W Kao
Journal:  J Mol Biol       Date:  2019-01-25       Impact factor: 5.469

4.  Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology.

Authors:  Winnie S Liang; Travis Dunckley; Thomas G Beach; Andrew Grover; Diego Mastroeni; Keri Ramsey; Richard J Caselli; Walter A Kukull; Daniel McKeel; John C Morris; Christine M Hulette; Donald Schmechel; Eric M Reiman; Joseph Rogers; Dietrich A Stephan
Journal:  Neurobiol Aging       Date:  2008-06-24       Impact factor: 4.673

Review 5.  Cathepsin D--many functions of one aspartic protease.

Authors:  Petr Benes; Vaclav Vetvicka; Martin Fusek
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-08       Impact factor: 6.312

6.  Cathepsin D SNP associated with increased risk of variant Creutzfeldt-Jakob disease.

Authors:  Matthew T Bishop; Gabor G Kovacs; Pascual Sanchez-Juan; Richard S G Knight
Journal:  BMC Med Genet       Date:  2008-04-21       Impact factor: 2.103

7.  Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology.

Authors:  Jean-Vianney Haure-Mirande; Mickael Audrain; Tomas Fanutza; Soong Ho Kim; William L Klein; Charles Glabe; Ben Readhead; Joel T Dudley; Robert D Blitzer; Minghui Wang; Bin Zhang; Eric E Schadt; Sam Gandy; Michelle E Ehrlich
Journal:  Acta Neuropathol       Date:  2017-06-13       Impact factor: 17.088

8.  Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40.

Authors:  Caitlin N Suire; Samer O Abdul-Hay; Tomoko Sahara; Dongcheul Kang; Monica K Brizuela; Paul Saftig; Dennis W Dickson; Terrone L Rosenberry; Malcolm A Leissring
Journal:  Alzheimers Res Ther       Date:  2020-07-06       Impact factor: 6.982

9.  Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated Functionality and Modified α-Synuclein Degradation Properties.

Authors:  Josina Bunk; Susy Prieto Huarcaya; Alice Drobny; Jan Philipp Dobert; Lina Walther; Stefan Rose-John; Philipp Arnold; Friederike Zunke
Journal:  Front Cell Dev Biol       Date:  2021-02-11

10.  Lack of association between cathepsin D C224T polymorphism and Alzheimer's disease risk: an update meta-analysis.

Authors:  Cuiju Mo; Qiliu Peng; Jingzhe Sui; Jian Wang; Yan Deng; Li Xie; Taijie Li; Yu He; Xue Qin; Shan Li
Journal:  BMC Neurol       Date:  2014-01-15       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.